Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for uremic toxins in sepsis-induced cardiorenal syndrome
ChiCTR2500109907Phase 4Not yet recruiting
- Sponsor
- Guangdong Second Provincial Traditional Chinese Medicine Hospital
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of nesiritide in cardiorenal syndrome (CRS), sepsis, acute kidney failure (AKF) and 1 more (2 arms), sponsored by Guangdong Second Provincial Traditional Chinese Medicine Hospital. Primary endpoint: NT-proBNP. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
cardiorenal syndrome (CRS)sepsisacute kidney failure (AKF)heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2500109907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109907.